Clinical TrialID 3723
Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate
NCT02171624
Healthy
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 3723
- Evidence Id
- 3723
- Core Evidence Id
- 3723
- Source Clinical Trial Id
- 3696
- Herb2 Clinical Trial Id
- HBCT003696
- Nct Id
- NCT02171624
- Title
- Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate
- Status
- Completed
- Phase
- Phase 1
- Study Result
- No
- Study Condition
- Healthy
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: dabigatran etexilate|DRUG: quinidine
- Intervention Allocation
- Randomized
- Intervention Model
- Crossover
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult
- Enrollment
- 42
- Outcome Measure
- Differences between treatments in systolic blood pressure profiles (using area under the BP-time curve), -0:15 before, and every 15 minutes for 2 hours post-dose, 3, 4 and 12 hours post dose|Incidence of symptomatic hypotension, -0:15 before, and every 15 minutes for 2 hours post-dose, 3, 4 and 12 hours post dose
- Sponsor Collaborator
- Boehringer Ingelheim
- Funded By
- INDUSTRY
- Location
- Other Id
- 1160.9
- Start Date
- 2009-03
- Primary Completion Date
- 2009-04
- Completion Date
- First Posted
- 2014-06-24
- Results First Posted
- Last Update Posted
- 2014-06-24
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT02171624
- Title Cn
- Title En
- Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate
- Bilingual Status
- semi_complete